VG Acquisition Corp.

VG Acquisition Corp. operates as a blank check company. It is created for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Richard Charles Nicholas Branson on February 19, 2020 and is headquartered in New York, NY. Redemption Price: 10. Warrant Coverage: 1/3.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

The Special Purpose Acquisition Company (SPAC) begins trading publicly. During this phase, the SPAC looks for a target company to merge with.

SEARCHING PHASE

The SPAC announces which company it will be acquiring (and taking public).

PREVIOUS PHASE

Investors and shareholders will meet to approve the acquisition.

CURRENT PHASE

VGAC stock has slumped, perhaps because investors were hoping for a different merger partner. But the 23andMe deal looks like a winner.

23andMe Merger Makes VG Acquisition Stock a Buy

Andina Acquisition Corp III

Camber Energy

CoreLogic

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor...

SHAREHOLDER ALERT: WeissLaw LLP Reminds VKIN, CLGX, VGAC, and ANDA Shareholders About Its Ongoing Investigations

Holicity

Snowflake

Rover has an amazing business model -- it's the Airbnb for dogs.

4 Reasons I Just Bought This SPAC Stock

23andMe is facing negative publicity and potentially tough competition, making VGAC stock unattractive at this point. The post 23andMe's Challenges Make VGAC Stock Unattractive appeared first on InvestorPlace.

23andMe's Challenges Make VGAC Stock Unattractive

With more than 50% possible downside, and questionable upside, there's little reason to dabble in VGAC stock at today's prices. The post VG Acquisition Stock Will Continue to Underwhelm SPAC Investors appeared first on InvestorPlace.

VG Acquisition Stock Will Continue to Underwhelm SPAC Investors

With the general excitement toward ancestry research, VGAC stock has tremendous appeal due to its merger with 23andMe. However, you should look into the science first before proceeding.

Be Careful About All the 23andme Hype Underpinning VG Acquisition Stock

Virgin Galactic

Virgin Galactic is off to a ridiculous start in 2021, as SPCE stock rises over 130%. Now's the time to diversify your Richard Branson bets.

Virgin Galactic or 23andMe: Which Is the Better Buy?

VG Acquisition Corp's SPAC deal with 23andMe.com is too speculative. VGAC stock is not worth more than $8.38, despite the exciting SPAC merger deal.

VG Acquisition Corp's SPAC Deal With 23andMe Is Too Speculative

Gigcapital2

These "blank-check companies" are taking over the most innovative and fastest-growing opportunities in the healthcare industry.

2 Healthcare SPACs to Watch in 2021

Consumer genetic testing is trendy, but it may not be profitable (yet).

23andMe Is Going Public Via a SPAC. Here's What You Need to Know

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of VG Acquisition Corp. - VGAC

23andMe Inc (NYSE:ME), which sells home DNA testing kits and sells the rights to drug developers, is joining the IPO frenzy by reversing into a cash-rich shell company backed by Sir Richard Branson. As part of the merger with VG Acquisition Corp (NYSE:VGAC), a special purpose acquisition company (SPAC) founded by Branson, the DNA testing company will raise US$759mln.

DNA testing company 23andMe to float using Richard Branson's cash shell

At-home DNA testing company scheduled to go public through SPAC

Will Privacy Issues Curtail 23andMe's Growth?

"VGAC" now definitely doesn't stand for "Virgin Galactic."

Why Virgin Galactic and VG Acquisition Stocks Both Dropped Today

Personalized DNA testing company 23andMe is going public with a SPAC deal announced Thursday. The SPAC Deal: 23andMe is going public with VG Acquisition Corp (NYSE: VGAC), a SPAC from Virgin Group.

DNA, Genomics Company 23andMe Gets SPAC Deal: What Investors Should Know

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of VG Acquisition Corp. ("VGAC" or the "Company") (NYSE: VGAC) in connection with the Company's proposed merger with 23andMe, Inc....

SHAREHOLDER ALERT: WeissLaw LLP Investigates VG Acquisition Corp.

Digital health's SPAC party is just getting started. 23andMe, the 14-year-old consumer genetic-testing company, added to the fray Thursday when it announced its intention to merge with Richard Branson's blank-check holding company, VG Acquisition. The deal would value 23andMe at $3.5 billion.

We spoke with the CEO of 23andMe about the future of the consumer genetics industry and why she wouldn't have considered a SPAC deal 6 months ago

The genetic testing company is about to get a much-needed capital infusion.

23andMe Going Public Via Merger With Virgin Group SPAC

23andMe, a consumer genetics company, is going public via a merger with Richard Branson's special-purpose acquisition corporation, or SPAC, VG Acquisition Corp., in a deal with an enterprise value of about $3.5 billion, the companies said Thursday.

23andMe is going public via a merger with Richard Branson's blank-check company

A blank-check firm backed by Virgin Group founder Sir Richard Branson is taking consumer DNA-testing firm 23andMe public in a deal that values the merged entity at $3.5 billion, the companies said Thursday. As part of the deal with VG Acquisition, 23andMe will receive proceeds of $759 million, which includes $250 million from a range of investors including Branson, 23andMe co-founder.

23andMe going public with help of Richard Branson-backed SPAC

The blank check company found its target, and investors are thrilled.

Richard Branson's SPAC Is Soaring on Thursday -- Here's Why

WILMINGTON, Del., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating VG Acquisition Corp. (“VG Acquisition”) (NYSE: VGAC) regarding possible breaches of fiduciary duties and other violations of law related to VG Acquisition's agreement to merge with 23andMe, Inc.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of VG Acquisition Corp. Merger

The latest in a long line of companies pursuing alternative ways to go public, popular DNA-testing and research company 23andMe Inc. announced a cash-and-stock deal with special purpose acquisition company VG Acquisition Corp. (NYSE:VGAC) on Thursday.

23andMe to Go Public Via SPAC

23andMe, the consumer genetics company that popularized at home DNA test kits, is going public via merger with a SPAC. The company will merge with Richard Branson's VG Acquisition Corp. in a deal that gives 23andMe an enterprise value of $3.5 billion. Anne Wojcicki, CEO and co-founder of the company, and Richard Branson will each invest $25 million in the deal.

23andMe to go public via SPAC with backing from Richard Branson in $3.5 billion deal

23andMe has revealed plans to go public via a SPAC merger with VG Acquisition (VGAC) and shares of VGAC stock are soaring on Thursday. The post VGAC Stock: 15 Things to Know About 23andMe and the Virgin Group SPAC Merger appeared first on InvestorPlace.

News for VG Acquisition Corp. Stock (VGAC)